PD-004Baseline characteristics and second-line treatment for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line FOLFIRINOX, gemcitabine+nab-paclitaxel or gemcitabine-monotherapy in routine clinical practice across Europe

Introduction: Both FOLFIRINOX and gemcitabine+nab-paclitaxel have shown superior overall survival over gemcitabine-monotherapy in fitter and younger first-line mPAC patients, but with increased toxicity. No randomized phase III data comparing FOLFIRINOX and gemcitabine+nab-paclitaxel are available to help clinical decision making. Furthermore, data on systemic treatment choices in first-line mPAC and outcomes outside clinical trials are scarce. The goal of this large pan-European project was to generate data on diagnosis, treatment patterns and outcomes from the records of patients who completed first-line mPAC treatment across Europe.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research